永安药业(002365) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥196,644,532.11, a decrease of 36.80% compared to ¥311,166,729.63 in the same period last year[5] - Net profit attributable to shareholders increased by 91.42% to ¥28,680,093.28 from ¥14,983,070.77 year-on-year[5] - The net profit excluding non-recurring gains and losses surged by 247.61% to ¥19,973,413.26 compared to ¥5,745,988.18 in the previous year[5] - The company reported a significant increase in investment income, which rose by 232.76% to ¥6,293,983.84 from ¥1,891,449.70 in the previous year[10] - The company’s total profit for the period was ¥33,833,677.38, reflecting a 124.66% increase from ¥15,059,977.50 in the same period last year[10] - The net profit for Q1 2024 was CNY 28,476,157.30, representing a 108.5% increase compared to CNY 13,694,733.08 in Q1 2023[24] - The total revenue from operating activities was CNY 340,927,128.64, an increase from CNY 301,450,313.82 in the previous year[25] - The operating profit for Q1 2024 was CNY 34,147,399.94, compared to CNY 15,321,664.22 in Q1 2023, marking a 122.5% increase[24] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥4,904,038.98, a decline of 110.13% from ¥48,405,966.87 in the same period last year[5] - Net cash flow from operating activities decreased by 110.13%, from 48,405,966.87 to -4,904,038.98, mainly due to substantial receivables from the previous period[11] - Net cash flow from investing activities improved by 35.65%, from -86,991,761.53 to -55,978,437.10, attributed to a reduction in the amount of financial products purchased[11] - Net cash flow from financing activities decreased by 81.73%, from -30,082,708.33 to -5,496,533.60, primarily due to loan repayments by a subsidiary[11] - Cash and cash equivalents decreased to ¥244,645,727.87 from ¥326,171,803.22, a decline of 25.0%[20] - The cash flow from operating activities showed a net outflow of CNY -4,904,038.98, a significant decrease from the previous year's inflow of CNY 48,405,966.87[25] - The cash and cash equivalents at the end of Q1 2024 were CNY 229,945,727.87, down from CNY 204,759,330.06 in the same period last year[26] Shareholder Information - Total assets at the end of the reporting period were ¥2,321,955,985.52, a decrease of 1.07% from ¥2,347,138,093.66 at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 1.42% to ¥2,012,101,231.82 from ¥1,983,913,143.72[5] - The total number of ordinary shareholders at the end of the reporting period was 27,867[13] - The largest shareholder, Chen Yong, holds 21.54% of the shares, totaling 63,468,000 shares[13] Cost Management - The company experienced a 90.27% reduction in selling expenses, down to ¥3,928,698.55 from ¥40,395,430.67, primarily due to the termination of a subsidiary's business[10] - Total operating costs for Q1 2024 were ¥175,009,541.52, down 43.4% from ¥309,419,184.44 in the previous period[22] - The company is focusing on cost control measures, as indicated by the significant reduction in sales and management expenses compared to the previous period[22] Legal and Regulatory Matters - The company is actively involved in ongoing patent litigation in the U.S., with recent rulings favoring the company regarding its manufacturing processes[14] - The company maintains normal export and sales activities for its taurine products in the U.S. despite ongoing legal challenges[14] - The company has approved several related party transactions for 2024, including agreements with Hubei Yongbang Engineering Technology Co., Ltd. and Zhejiang Shuangzi Intelligent Equipment Co., Ltd.[15]